XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial
Objectives:
To investigate whether XueBiJing injection improves clinical outcomes in critically ill patients with severe community-acquired pneumonia.
Design:
Prospective, randomized, controlled study.
Setting:
Thirty-three hospitals in China.
Patients:
A total of 710 adults 18–75 years old with severe community-acquired pneumonia.
Interventions:
Participants in the XueBiJing group received XueBiJing, 100 mL, q12 hours, and the control group received a visually indistinguishable placebo.
Measurements and Main Results:
The primary outcome was 8-day improvement in the pneumonia severity index risk rating. Secondary outcomes were 28-day mortality rate, duration of mechanical ventilation and total duration of ICU stay. Improvement in the pneumonia severity index risk rating, from a previously defined endpoint, occurred in 203 (60.78%) participants receiving XueBiJing and in 158 (46.33%) participants receiving placebo (between-group difference [95% CI], 14.4% [6.9–21.8%]; p
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Clinical Investigations Source Type: research